The information you provide to the chat will be collected and recorded to improve your experience and for quality assurance. Please read our privacy policy to see how we are storing and protecting your data.
How can we help you today?

Lentivirus (LV) production services

Your trusted partner in LV development and manufacturing

Enter a world of dependable, cutting-edge solutions through our clinical and commercial lentiviral vector manufacturing service.

We’ve manufactured LV for a total of:

530+ total batches

40+ clinical batches

465+ commercial/PPQ batches

We excel in providing high-quality vectors tailored to fulfill your commercial production requirements. Our team has vast experience producing many common lentiviral vector pseudotypes via transient transfection (primarily using HEK293T cell line), an unwavering commitment to high quality standards, and an impeccable track record in manufacturing commercially approved lentiviral vectors. Effortlessly transition from development to large-scale commercial production with our seamlessly scalable manufacturing processes.

What sets us apart:

  • Batch excellence: With over 530 batches successfully manufactured, including 40+ clinical batches and 465+ commercial/ PPQ, we have a proven track record of excellence.
  • Customized approach: Tailor your lentiviral vectors to match the specific requirements of your commercial applications, ensuring optimal performance.
  • Regulatory compliance: Our GMP-compliant manufacturing processes guarantee adherence to regulatory standards, instilling confidence in the approval process.

Our team is experienced in supporting a variety of other viral platforms. For questions about our additional capabilities and capacity, please contact us.

LV by pseudotype experience:

Helpful Resources

Blog

Blog

Viral vector commercialization – Part 1: Tech transfer process for commercial viral vector manufacturing

Learn how tech transfers can help develop and manufacture viral vectors at scale, accelerate vaccine and gene therapy commercialization, and provide expertise.

Read Blog
Blog

Blog

Viral vector commercialization – Part 2: Best practices in process validation lifecycle

Learn more about the robust viral vector process validation cycle, which includes various assessments and studies to ensure the safety, efficacy, and quality of viral vectors.

Read Blog
Article

Article

Strategies to accelerate drug development through harmonization of early and late stage processes

This technical article presents a harmonized and streamlined approach established at Thermo Fisher Scientific for manufacturing AAV and LV vectors for discovery research using technologies and processes mirroring current GMP platforms.

View Article
Webinar

Webinar

Preparing viral vector productions for commercialization

Gene therapy vectors are rapidly approaching the commercial space so commercial readiness is critical for success. Watch our webinar to learn about our capabilities and approaches for preparing viral vectors for commercialization.

View Webinar
Infographic

Infographic

Regulatory pathways for CGT and ATMP products

CGT is one of the world's fastest-growing therapeutic areas today. Instead of treating patients for the rest of their lives, these therapies offer them hope of a cure. In this infographic, we will review three tips for achieving regulatory success.

 

View Infographic
eBook

eBook

Cell and gene therapies in the US vs. the EU: Top five areas of differentiation

In this eBook we share the five key differences in the drug development and review process for companies hoping to gain market access through US Food and Drug Administration (FDA) or European Medicines Agency (EMA) approval—as well as tips for navigating these differences.

 

View Article